Clinical Trials Logo

PD-1 Antibody clinical trials

View clinical trials related to PD-1 Antibody.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05775705 Not yet recruiting - Lymphoma Clinical Trials

L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH

Start date: August 1, 2023
Phase: Phase 3
Study type: Interventional

The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.

NCT ID: NCT05461235 Not yet recruiting - PD-1 Antibody Clinical Trials

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

Start date: July 15, 2022
Phase: Phase 2
Study type: Interventional

This is a prospective, open, single-arm Phase II clinical study to evaluate the efficacy and safety of anti-PD-1 antibody combined with autologous DC and NK cells in the treatment of digestive carcinoma.

NCT ID: NCT04944511 Not yet recruiting - PD-1 Antibody Clinical Trials

PD-1 Antibody Improve Mixed Chimerism

HLH
Start date: July 1, 2021
Phase: N/A
Study type: Interventional

PD-1/PD-L1 pathway play an important role in Inhibiting the function of antigen-specific CD8+T cells, thus matter a lot in immune escape. We intend to use PD-1 antibody to improve the function of lymhocyte and improve the chimerism in patients after allo-HCT.

NCT ID: NCT04834674 Not yet recruiting - Clinical trials for Intrahepatic Cholangiocarcinoma

DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma

Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above. Its incidence accounts for about 15%-20% of primary liver malignancies, showing a gradually increasing trend. Surgical resection is currently the main method for the treatment of ICC. However, most (60% -70%) patients are diagnosed at the advanced stage. Gemcitabine plus cisplatin is the standard first-line incurable resection recommended in international and domestic guidelines. There is not a standard second-line treatment that has progressed after standard first-line chemotherapy. The clinical benefits of immune therapies for HCC are emerging. Early clinical data already show the safety of immune checkpoint inhibition. This study is to analyze the safety and efficacy of drug-eluting beads transarterial chemoembolization combined with apatinib and carrelizumab injection in the treatment of ICC that has progressed after standard first-line chemotherapy. Patients who were aged 18 to 80 years with a histological or cytological diagnosis of ICC,locally advanced or multiple liver metastases, including progression after gemcitabine chemotherapy, will be enrolled in this trial.

NCT ID: NCT04108013 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC

Start date: October 8, 2019
Phase: Phase 2
Study type: Interventional

This study is a randomized, controlled, open-label, prospective, single-center phase II clinical study. Target population is patients with stage II and IIIA resectable non-small cell lung cancer who had not received systemic chemotherapy. Study objective is to evaluate the major pathologic response of SHR-1210 + carboplatin + paclitaxel-albumin in subjects with resectable non-small cell lung cancer. SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.

NCT ID: NCT03777124 Not yet recruiting - Chemotherapy Effect Clinical Trials

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Start date: February 2019
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, multi-center, phase II trial to evaluate the efficacy and safety of SHR-1210 plus apatinib mesylate versus Pemetrexed and Carboplatin in Subjects with KRAS mutant stage IV non-squamous Non-small Cell Lung Cancer